Developing antifibrotic and anti-inflammatory therapeutics in clinical stage for common and rare renal diseases including CKD and Alport syndrome
Time: 11:30 am
day: Day 2 Track 2 AM
Details:
- Developing Vonafexor in the Proof-Of-Concept Phase 2 study “ALPESTRIA-1” in Alport syndrome
- Validating efficacy of Vonafexor on kidney function and kidney remodeling in a severe preclinical mouse model for CKD as much as for Alport syndrome
- Expanding Vonafexor analog development to larger kidney indications
